Home > Cardiology > SGLT2 inhibitors may lower the risk of major cardiovascular events

SGLT2 inhibitors may lower the risk of major cardiovascular events


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
BMJ
Reuters Health - 25/09/2020 - Sodium glucose transporter 2 (SGLT2) inhibitors may lower the risk of major cardiovascular events in people with type 2 diabetes more effectively than dipeptidyl peptidase-4 inhibitors (DPP-4), a new study suggests. In a retrospective study that included 209,867 new users of an SGLT2 inhibitor who were matched to 209,867 users of a DPP-4 inhibitor, the SGLT2 users were nearly 25% less likely to experience a major adverse cardiovascular event (MACE), according to the report published in The BMJ. "These findings confirm that the benefits of these drugs demonstrated in the controlled setting of clinical trials extend to the real-world setting of everyday clinical practice," said lead author Kristian Filion of McGill University and the Lady Davis Institute of the Jewish General Hospital. But SGLT2 inhibitors may not be for everybody, Filion said in an email. "While this study confirms the effectiveness of SGLT2 inhibitors for ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on